Q1 Round Up: Under Pressure

The first quarter of the year got off to a predictably shaky start for a biopharma market which is marked by increasing uncertainty and turmoil. Huge cuts at the FDA, coupled with the will-they/won’t-they situation on tariffs for pharmaceutical...Contents

Foreword

First Quarter M&A Activity Rose On The Strength Of Three Deals

Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings

Q1 VC Financings Fall Short As Early Deals, Mega-Rounds Dip Last-Minute $600m Push Didn’t Save Quarter

HOW WE HELP